GSK/Pentraxin: Targeting SAP in Amyloidosis, and Maybe Alzheimer's Too
This article was originally published in Start Up
Executive Summary
University College London spin-out Pentraxin's February 2009 tie-up with GlaxoSmithKline in amyloidosis showed GSK's willingness to invest in risky, early-stage research. Weeks later, Pentraxin announced promising clinical data with a related program in Alzheimer's, raising the possibility that this alliance may yet expand beyond a specialist niche.